NCT01426230View on ClinicalTrials.gov

Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia

CompletedOBSERVATIONAL
Enrollment

201

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

April 30, 2012

Conditions
Post Herpetic Neuralgia
Trial Locations (37)

Unknown

Mobile

Tuscaloosa

Phoenix

Sun City

Tucson

Fresno

San Francisco

Fairfield

Lauderdale Lakes

Naples

North Palm Beach

Ormond Beach

Palm Beach

Sunrise

Marietta

Bolingbrook

Evansville

Lexington

Brighton

Worcestor

Jefferson City

St Louis

Tom River

Hickory

Raleigh

Allentown

Altoona

Wyomissing

Mt. Pleasant

Cordova

Austin

Bedford

Corpus Christi

Houston

San Antonio

Orem

Edmonds

Sponsors

Lead Sponsor

Depomed
All Listed Sponsors
lead

Depomed

INDUSTRY

NCT01426230 - Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia | Biotech Hunter | Biotech Hunter